Catalent and Cevec Pharmaceuticals have joined forces to offer cell line development and manufacturing services to biotechs.
The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.
The deal follows a joint-study for complex protein production, which saw “record” yields of non-antibody proteins produced in a human expression system.
In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative proprietary technologies.”
Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”